share_log

东星医疗(301290.SZ)拟设立控股子公司东星生物医药 拓展新的产品业务领域

Dongxing Medical (301290.SZ) plans to establish a holding subsidiary, Dongxing Biomedical, to expand into new business areas for biomedical products.

Zhitong Finance ·  Sep 18 17:09

Dongxing Medical (301290.SZ) announced that the company plans to establish Dongxing Biomedical Co., Ltd. (tentative name, "Dongxing Biomedical") together with the controlling shareholder and actual controller Wan Shiping, and its directly controlled Changzhou Guoxing Investment Management Co., Ltd., the actual controller and director, deputy general manager Wan Zhengyuan, the director and general manager Wei Jiangang, the director and deputy general manager, board secretary, and CFO Gong Aiqin, as well as non-related party Haile. The registered capital of Dongxing Biomedical is 20 million yuan, of which the company plans to invest 11 million yuan, accounting for 55%.

Dongxing Medical (301290.SZ) announced that the company plans to establish Dongxing Biomedical Co., Ltd. (tentative name, "Dongxing Biomedical") together with the controlling shareholder and actual controller Wan Shiping, and its directly controlled Changzhou Guoxing Investment Management Co., Ltd., the actual controller and director, deputy general manager Wan Zhengyuan, the director and general manager Wei Jiangang, the director and deputy general manager, board secretary, and CFO Gong Aiqin, as well as non-related party Haile. The registered capital of Dongxing Biomedical is 20 million yuan, of which the company plans to invest 11 million yuan, accounting for 55%.

It is reported that the company will gather outstanding scientific and technological personnel through the target company, establish collaborative relationships between industry, academia, and research institutes with well-known universities and research institutes, expand new business areas with the help of research institutes and universities' platforms and resources, further consolidate the company's core competitiveness, extend the industrial chain, and cultivate new profit growth points.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment